Racial differences in the incidence of skin rashes after EGFR‐TKI therapy have been observed with erlotinib with rates of 82% in Asians and 68% in non‐Asians and with afatinib with rates of 45.8% in Asians and 35.9% in non‐Asians for paronychia.15, 16. Here, EGFR is linked to paronychia.